Please login to the form below
Yuhan
This page shows the latest Yuhan news and features for those working in and with pharma, biotech and healthcare.
AZ’s Tagrisso approved for EGFR-positive NSCLC in the EU
NSCLC. Janssen assessed the investigational drug in combination with EGFR tyrosine kinase inhibitor (TKI) lazertinib, which the company licensed from South Korean pharma firm Yuhan in 2018.
Latest news
-
Janssen’s EGFR-targeting treatment regimen shows early benefit in lung cancer
NSCLC. Janssen assessed the investigational drug in combination with EGFR tyrosine kinase inhibitor (TKI) lazertinib, which the company licensed from South Korean pharma firm Yuhan in 2018.
-
J&J’s bispecific lung cancer antibody nabs FDA breakthrough status
China’s Yuhan Corp in 2018 for $50m upfront and up to $1.25bn in potential development and commercial milestones.
-
FDA clears wider use for Boehringer’s Ofev in lung disease
followed earlier deals with Bridge Biotherapeutics for an Ofev follow-up and Yuhan focusing on lover fibrosis.
-
Boehringer bolsters NASH pipeline with Enleofen link-up
The last couple of years have seen the German group license an Ofev follow-up from Bridge Biotherapeutics and agree an $870m tie-up with Yuhan for a NASH candidate.
-
CymaBay Therapeutics plummets after abandoning NASH drug
German drugmaker Boehringer is also looking to enter the market, after it signed a $870m licence deal with South Korean biotech Yuhan in July to bolster its NASH pipeline. ... The deal will draw on Yuhan’s expertise in fibroblast growth fact 21
More from news
Approximately 1 fully matching, plus 8 partially matching documents found.
Latest Intelligence
-
Country report: The healthcare market in South Korea
684. 43. 2. Hanmi Pham. 539. 59. 3. Yuhan. 519. 32.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Pfizer reports positive results for elranatamab in multiple myeloma
- BMS presents positive four-year results for Opdivo combination in lung cancer
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- AstraZeneca shares positive phase 3 results for Tagrisso in lung cancer
- Merck sues US government over Medicare drug price negotiation programme
- How to Increase Engagement During Virtual Events
- AstraZeneca to stop post-marketing study of Andexxa following early success
- Janssen shares positive phase 3 results for erdafitinib in bladder cancer
- Generative AI is coming for healthcare
- Merck sues US government over Medicare drug price negotiation programme
- GSK’s RSV vaccine approved by European Commission for older adults
No results were found
PMHub
Anthill Agency
Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...
Latest intelligence
- The 17th World Congress on Controversies in Neurology
- This year, there was a focus on the rare disease neuromyelitis optica spectrum disorder that strikes suddenly and mainly impacts women...
- Archetypes: Rethinking go-to-market expectations to drive commercial success
- In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...
- Tuberculosis – why it remains a major global public health challenge
- Innovative collaboration is required to address the major public health challenges around TB and expedite drug development...
